Bio-Techne

264 articles with Bio-Techne

• Bio-Techne Further Enhances Its Gene Engineering & Cell & Gene Therapy Manufacturing Capabilities

  6/10/2021

  Bio-Techne Corporation has partnered with Autolomous to implement a first of its kind electronic batch record system, AutoloMATETM, at Bio-Techne's GMP cellular manufacturing center.

• Bio-Techne Joins Cell and Gene Therapy Catapult Process Analytical Technology Consortium

  6/8/2021

  Bio-Techne Corporation announced it is joining the Cell and Gene Therapy Catapult process analytical technology consortium, which includes over 20 pharmaceutical companies, technology providers, therapy developers, and charities.

• Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order

  6/2/2021

  COVID-SeroKlir detects both the presence and precise level of neutralizing IgG antibodies with 98.8% sensitivity and 99.6% specificity

• Bio-Techne To Present At The Jefferies Virtual Healthcare Conference - May 19, 2021

  5/19/2021

  Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:00 p.m. EDT.

• Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications

  5/18/2021

   Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella.

• Multisite Study Demonstrates Utility of Asuragen Kit for Identifying Variants Linked to Spinal Muscular Atrophy

  5/10/2021

  One kit provides comprehensive, reproducible detection of variants for diagnostics and carrier screening using a simple workflow that produces results in less than four hours

• Bio-Techne Releases Third Quarter Fiscal 2021 Results

  5/6/2021

  The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States.

• Bio-Techne Declares Dividend - May 06, 2021

  5/6/2021

  Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2021.

• Bio-Techne and 908 Devices Announce Joint Collaboration

  5/4/2021

  Bio-Techne Corporation and 908 Devices announced a joint collaboration to develop an extended workflow solution for protein characterization.

• 908 Devices and Bio-Techne Announce Joint Collaboration

  5/4/2021

  908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple branded protein analysis portfolio of products

• Bio-Techne Announces Commercial Release of Novel DNAscope™ in situ Hybridization Assays for Chromogenic Detection of DNA Copy Number and Structural Variations

  4/27/2021

  Bio-Techne Corporation announced the expansion of the Advanced Cell Diagnostics, a Bio-Techne brand, RNAscope™ technology with release of new DNAscope Assays.

• Bio-Techne Announces Licensing of Proprietary Antibody to Xencor for Therapeutic Development

  4/14/2021

  Bio-Techne Corporation announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, for its therapeutic development pipeline.

• Bio-Techne Announces Commercial Release of Abby Automated Western System for Simple Western and Introduces Stellar Modules for Jess

  4/8/2021

  Abby is the next generation chemiluminescence Western protein analyzer and Stellar modules set the standard for fluorescence sensitivity

• Bio-Techne To Host Conference Call On May 6, 2021 To Announce Third Quarter 2021 Financial Results

  4/6/2021

   Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, May 6, 2021 , at 8:00 a.m. CDT to review third quarter 2021 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 6, 2021

• Bio-Techne Completes Acquisition of Asuragen, Inc.

  4/6/2021

  Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc.  The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones. 

• Bio-Techne Announces Launch of Cultrex UltiMatrix BME to Support Organoid and Pluripotent Stem Cell Cultures

  3/29/2021

   Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extracellular matrix hydrogel that provides significant performance and consistency benefits for culturing organoids and pluripotent stem cells.

• Bio-Techne Announces Receipt of COVID-19 Innovation Award from CiteAb

  3/26/2021

  Bio-Techne Corporation announced that its R&D Systems and Novus brands have been named winners of the CiteAb COVID-19 Innovation Award.

• Bio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test

  3/23/2021

  Bio-Techne Corporation announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic version of the ExoDx™ Prostate test kit enabling self-certification as CE-IVD as of March 22, 2021.

• Bio-Techne Announces ISO 9001:2015 Certification for its Bristol Manufacturing Facility.

  3/15/2021

  Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that its Bristol site in the United Kingdom received ISO 9001:2015 Quality Management Systems certification.

• Bio-Techne Announces ExoTRU Kidney Transplant Rejection Assay Data Publication

  3/8/2021

   Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU™ (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA assay.